Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.
Ea Maria Tønning TønnesenMagnus StougaardPeter MeldgaardJohanne Lade-KellerPublished in: Journal of clinical pathology (2022)
may serve as a potential biomarker for survival benefits with immunotherapy.
Keyphrases